Comparaison de l’ixékizumab et du guselkumab : réponses cliniques sur 24 semaines et données sur l’expression des gènes sur 4 semaines
Sign Up to like & getrecommendations! Published in 2020 at "Annales De Dermatologie Et De Venereologie"
DOI: 10.1016/j.annder.2020.09.546
Abstract: Introduction L’objectif de l’etude IXORA-R etait de comparer l’efficacite de l’antagoniste de l’interleukine (IL)-17A, l’ixekizumab (IXE), et de l’inhibiteur de l’IL-23p19, le guselkumab (GUS), sur une periode de 24 semaines de traitement. Dans IXORA-R, le pourcentage de… read more here.
Keywords: par; ixe; sur semaines; expression des ... See more keywords
Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2022.2081417
Abstract: Abstract Aims To compare long-term healthcare resource utilization (HCRU) and costs among patients who initiated ixekizumab (IXE) or adalimumab (ADA) for treatment of psoriasis in the United States. Methods Adult patients with psoriasis who had… read more here.
Keywords: ada users; ixe ada; healthcare resource; resource utilization ... See more keywords
P193 Clinical features of patients with active ankylosing spondylitis who did not respond to adalimumab but responded to ixekizumab: a post-hoc analysis
Sign Up to like & getrecommendations! Published in 2021 at "Rheumatology"
DOI: 10.1093/rheumatology/keab247.188
Abstract: Background/Aims Biologic treatment in ankylosing spondylitis (AS) are currently limited to TNF and IL-17A inhibitors (IL-17Ai). It is unknown whether there are predictors of AS patients who only respond to 1 of these mechanisms of… read more here.
Keywords: ixe; eli lilly; novartis; shareholder ... See more keywords
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
Sign Up to like & getrecommendations! Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-219717
Abstract: Objectives The objective of COAST-Y was to evaluate the effect of continuing versus withdrawing ixekizumab (IXE) in patients with axial spondyloarthritis (axSpA) who had achieved remission. Methods COAST-Y is an ongoing, phase III, long-term extension… read more here.
Keywords: week; achieved remission; coast; randomised withdrawal ... See more keywords